Verition Fund Management LLC acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,022 shares of the biopharmaceutical company’s stock, valued at approximately $129,000.
Several other hedge funds also recently modified their holdings of the stock. Trexquant Investment LP lifted its stake in Catalyst Pharmaceuticals by 19.3% in the 2nd quarter. Trexquant Investment LP now owns 86,951 shares of the biopharmaceutical company’s stock valued at $610,000 after purchasing an additional 14,094 shares during the last quarter. Profund Advisors LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $161,000. Virtu Financial LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $1,140,000. Raymond James Financial Services Advisors Inc. lifted its stake in Catalyst Pharmaceuticals by 26.9% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 300,013 shares of the biopharmaceutical company’s stock valued at $3,849,000 after purchasing an additional 63,674 shares during the last quarter. Finally, Prudential Financial Inc. lifted its stake in Catalyst Pharmaceuticals by 16.3% in the 3rd quarter. Prudential Financial Inc. now owns 1,492,625 shares of the biopharmaceutical company’s stock valued at $19,149,000 after purchasing an additional 209,580 shares during the last quarter. Institutional investors own 86.66% of the company’s stock.
Catalyst Pharmaceuticals Stock Down 2.7 %
Shares of CPRX stock opened at $14.64 on Friday. The firm has a 50 day moving average price of $16.77 and a two-hundred day moving average price of $15.57. The company has a market capitalization of $1.52 billion, a PE ratio of 24.00 and a beta of 1.16. Catalyst Pharmaceuticals, Inc. has a 12-month low of $6.15 and a 12-month high of $22.11.
Wall Street Analyst Weigh In
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms.
- Get a free copy of the StockNews.com research report on Catalyst Pharmaceuticals (CPRX)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.